» Articles » PMID: 27077687

SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains

Overview
Specialties Neurology
Psychology
Date 2016 Apr 15
PMID 27077687
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to describe SymptoMScreen, an in-house developed tool for rapid assessment of MS symptom severity in routine clinical practice, and to validate SymptoMScreen against Performance Scales (PS). MS patients typically experience symptoms in many neurologic domains. A tool that would enable MS patients to efficiently relay their symptom severity across multiple domains to the healthcare providers could lead to improved symptom management. We developed "SymptoMScreen," a battery of 7-point Likert scales for 12 distinct domains commonly affected by MS: mobility, dexterity, body pain, sensation, bladder function, fatigue, vision, dizziness, cognition, depression, and anxiety. We administered SymptoMScreen and PS scales to consecutive MS patients at a specialty MS Care Center. We assessed the criterion and construct validity of SymptoMScreen by calculating Spearmen rank correlations between the SymptoMScreen composite score and PS composite score, and between SymptoMScreen subscale and the respective PS subscale scores, where applicable. A total of 410 patients with MS (age 46.6 ± 12.9 years; 74% female; mean disease duration 12.2 ± 8.7 years) completed the SymptoMScreen and PSs during their clinic visit. Composite SymptoMScreen score correlated strongly with combined PS score (r = 0.88, p < 0.0001). SymptoMScreen sub scores correlated strongly with the criterion measures of the respective PS (r = 0.69-0.87, p < 0.0001). Test-retest reliability of SymptoMScreen and its subscales was excellent (r = 0.71-0.94, p < .0001). SymptoMScreen is a single-page battery of Likert scales that assesses symptom impact in 12 domains commonly affected in MS. It has excellent criterion and construct validity. SymptoMScreen is patient and clinician friendly, takes approximately one minute to complete, and can help better document, understand, and manage patients' symptoms in routine clinical practice. SymptoMScreen is freely available to clinicians and researchers.

Citing Articles

Artificial intelligence and science of patient input: a perspective from people with multiple sclerosis.

Helme A, Kalra D, Brichetto G, Peryer G, Vermersch P, Weiland H Front Immunol. 2025; 16:1487709.

PMID: 40034708 PMC: 11872699. DOI: 10.3389/fimmu.2025.1487709.


Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.

Salter A, Lancia S, Cutter G, Fox R, Marrie R Neurology. 2024; 104(2):e210149.

PMID: 39715473 PMC: 11666277. DOI: 10.1212/WNL.0000000000210149.


Assessing disease progression and treatment response in progressive multiple sclerosis.

Comi G, Dalla Costa G, Stankoff B, Hartung H, Soelberg Sorensen P, Vermersch P Nat Rev Neurol. 2024; 20(10):573-586.

PMID: 39251843 DOI: 10.1038/s41582-024-01006-1.


Association of Urinary Incontinence with Sensory-Motor Performance in Women with Multiple Sclerosis.

Ozden F, Ozkeskin M, Sari Z, Ekici E, Yuceyar N Int Urogynecol J. 2024; 35(12):2305-2311.

PMID: 38976027 DOI: 10.1007/s00192-024-05854-9.


The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event.

Zaratin P, Samadzadeh S, Seferoglu M, Ricigliano V, Silva J, Tunc A Front Neurol. 2024; 15:1407257.

PMID: 38974689 PMC: 11225898. DOI: 10.3389/fneur.2024.1407257.